Related Experiment Videos
Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients
1Medical Department B, Rikshospitalet, Oslo, Norway.
Insights
The new calcium channel blocker isradipine effectively reduced blood pressure in hypertensive heart transplant patients by lowering systemic vascular resistance. This resulted in improved cardiac output and reduced afterload, demonstrating its potential therapeutic benefits.
Area of Science:
- Cardiovascular Pharmacology
- Transplant Cardiology
- Hypertension Management
Background:
- Hypertension is a significant concern in cardiac transplant recipients.
- Calcium antagonists are a class of drugs used to manage hypertension.
- Isradipine is a novel calcium antagonist whose hemodynamic effects require investigation in specific patient populations.
Purpose of the Study:
- To evaluate the acute hemodynamic effects of intravenous isradipine in hypertensive cardiac transplant recipients.
- To assess the impact of isradipine on blood pressure, systemic vascular resistance, cardiac index, and left ventricular filling pressure.
Main Methods:
- Ten hypertensive cardiac transplant recipients underwent right heart catheterization.
- Isradipine (0.01 mg.kg-1) was administered intravenously.
- Hemodynamic parameters, including blood pressure, were measured noninvasively and invasively.
Main Results:
- Isradipine significantly reduced systolic blood pressure by 35 mmHg and diastolic blood pressure by 30 mmHg from a baseline of 164/114 mmHg.
- Systemic vascular resistance decreased by a maximum of 43%, leading to a 32% increase in cardiac index.
- The increase in cardiac index was primarily driven by enhanced stroke volume, with a modest 10% rise in heart rate; left ventricular filling pressure was slightly reduced.
Conclusions:
- Isradipine effectively reduces blood pressure in hypertensive cardiac transplant recipients.
- The primary mechanism of action involves a significant reduction in left ventricular afterload.
- These findings support the potential utility of isradipine in managing hypertension within this patient cohort.
Abstract:
The acute haemodynamic effects of the new calcium antagonist isradipine have been studied in ten hypertensive cardiac transplant recipients. Isradipine 0.01 mg.kg-1 was given IV during right heart catheterization and noninvasively automatic blood pressure measurements. From a baseline blood pressure of 164/114 mmHg the maximum blood pressure reduction was 35 mmHg systolic, 30 mmHg diastolic, and mean 34 mmHg, due to a reduction in systemic vascular resistance, maximum 43%. Cardiac index increased 32%, mainly due to an increase in the stroke volume, as the heart rate rose only by 10%. Left ventricular filling pressure was slightly reduced. We conclude that the main effect of isradipine was a major reduction in left ventricular afterload, comparable to that previously found in other patient groups.